Boston Scientific received FDA 510(k) clearance for its Asurys Fluid Management System on March 30, 2026, allowing the device to be marketed in the United States. The system is designed to provide irrigation and distention during endoscopic urologic procedures, addressing a critical need for fluid management and intrarenal pressure regulation.
The clearance expands Boston Scientific’s endoscopic urology portfolio and positions the company to capture a share of the growing market for advanced endoscopic equipment. The Asurys system pairs with the LithoVue Elite Single‑Use Digital Flexible Ureteroscope, enabling real‑time intrarenal pressure monitoring and on‑demand flush features that can reduce complications such as systemic inflammatory response syndrome, sepsis, and renal damage.
The Asurys system is part of Boston Scientific’s StoneSmart Solutions ecosystem, which includes products for kidney stone management, BPH, erectile dysfunction, and incontinence. The addition of fluid management technology complements existing offerings and strengthens the company’s strategy to provide comprehensive solutions in urology beyond its core cardiovascular and electrophysiology businesses.
Boston Scientific’s history of strategic acquisitions in the urology space, such as the 2015 purchase of Endo International’s urology portfolio, underscores its commitment to expanding this segment. The 510(k) clearance is a standard regulatory pathway that allows the company to market the device in the United States, opening a new revenue stream and enhancing competitive positioning against other urology device manufacturers.
The clearance represents a significant operational milestone that could drive future sales growth and reinforce Boston Scientific’s broader strategy to diversify its product portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.